Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) welcomes the preliminary results showing that its DurAVR™ transcatheter heart valve (THV) technology has restored normal pre-disease blood flow for the first time.
This technique performed well at 6 months compared to other transcatheter aortic valve replacements (TAVRs) and surgical aortic valve replacements (SAVRs).
Results presented at the conference
The results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston, the world’s largest conference of interventional cardiologists.
In a study comparing valve flow between current aortic valve replacement techniques in 22 patients, Anteris found no significant difference from normal healthy aortic valve flow using the DurAVR™ THV. showed.
When comparing current-generation TAVR and SAVR valves to healthy aortic valves, both groups showed statistically significant deterioration in blood flow.
Anteris CMO, Dr. Chris Meduri, said:
CEO Wayne Paterson said:
Shares are up around 5.3% to A$26.85 in early trading.
About Antelis Technologies
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) is a structural cardiac company focused on developing next-generation technologies that help healthcare professionals deliver consistent, life-changing outcomes for their patients.
Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of young, active aortic stenosis patients by providing durability with innovations designed to last for the rest of the patient’s life. corresponds to